Kodiak Sciences, Inc. (KOD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$35.36-2.75%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — EPS loss narrows toward consensus: FY26 EPS -3.95 vs -3.74 target; FY27 EPS -3.55 vs -3.12 target.
Kodiak Sciences is focused on developing treatments for retinal diseases. The company aims to maintain its cash runway into 2027. Analysts have recently revised EPS estimates upward, from -4.06 to -3.74 for 2026. The stock trades about 36% below consensus price levels, reflecting potential undervaluation if progress continues.
Kodiak has missed earnings in multiple recent quarters and remains loss-making. The EPS is expected to stay negative through 2027, with no revenue growth yet. The company’s cash runway is uncertain, and the recent selloff reflects elevated risk and weak execution.
The market prices in continued losses and a challenging path to profitability. The stock trades about 36% below consensus price levels, implying skepticism about near-term progress. Our view differs by focusing on the potential for cash runway maintenance and improving EPS revisions.
Breaks if: Cash runway falls short of covering operations into 2027
Ensure sufficient cash and cash equivalents to support current and planned operations through 2027.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state indicates a watchful approach due to recent performance and industry volatility.
The market appears to have low expectations for KOD, given its loss-making status and recent earnings misses. There is a sense of fragility in the stock, but no immediate signs of significant distress are evident.
Management is focused on advancing clinical programs, with key data readouts expected soon. However, the company's financial performance has been neutral, and its cash runway is declining, which adds to the uncertainty.
The long-term thesis hinges on the successful execution of clinical milestones and the performance of sector peers. Any negative guidance or worsening economic indicators could adversely affect KOD's outlook.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company missed Q2 earnings estimates, widening its net loss. This raises concerns about maintaining its cash runway into 2027. However, there is potential to advance Phase 3 assets and BLA filing, which could support future growth.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Cash and cash equivalents declined from $169.5 million in 2026-Q1 to $125.9 million in 2026-Q2. Management consistently affirms that current cash balances will support operations into 2027, indicating a stable but declining cash runway consistent with ongoing clinical investment.
“We expect that our current cash and cash equivalents will support our current and planned operations into 2027.”
“We believe that our current cash and cash equivalents will support our current and planned operations into 2027.”
“We believe that our current cash and cash equivalents will support our current and planned operations into 2027.”
Breaks if: EPS loss worsens or fails to improve toward consensus estimates in FY26 and FY27
Breaks if: Revenue fails to reach $57 million in FY27
Over the next 1 to 3 years, KOD's trajectory will depend on its ability to deliver on clinical promises amid a challenging market backdrop. Not investment advice.